|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 766.60 USD | +1.67% |
|
+1.19% | -0.70% |
| Jan. 22 | Jefferies Adjusts Price Target on Eli Lilly to $1,020 From $996 | MT |
| Jan. 22 | Robeco Global Consumer Trends down 0.37% in December - up in Novo Nordisk and Eli Lilly | FW |
| Capitalization | 679B 652B 616B 550B 976B 58,654B 1,080B 7,473B 2,744B 24,222B 2,546B 2,493B 105,916B | P/E ratio 2024 * |
61x | P/E ratio 2025 * | 35.5x |
|---|---|---|---|---|---|
| Enterprise value | 701B 673B 636B 568B 1,008B 60,559B 1,115B 7,716B 2,833B 25,009B 2,629B 2,574B 109,356B | EV / Sales 2024 * |
15.5x | EV / Sales 2025 * | 11.9x |
| Free-Float |
99.81% | Yield 2024 * |
0.68% | Yield 2025 * | 0.78% |
More valuation ratios
* Estimated data
More news
Last Transcript: Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | -0.22% | ||
| 1 week | +2.66% | ||
| Current month | -0.70% | ||
| 1 month | -0.15% | ||
| 3 months | -15.68% | ||
| 6 months | -11.47% | ||
| Current year | -0.70% |
1 week
725.01
766.60
1 month
725.01805.34
Current year
725.01805.34
1 year
624.68972.53
3 years
231.87972.53
5 years
117.06972.53
10 years
64.18972.53
| Director | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 57 | 2016-12-31 |
Ruth Gimeno
PSD | President | - | - |
Lucas Montarce
DFI | Director of Finance/CFO | 48 | 2024-09-08 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jon Fyrwald
BRD | Director/Board Member | 64 | 2004-12-31 |
Ralph Alvarez
BRD | Director/Board Member | 68 | 2009-03-31 |
| Director/Board Member | 53 | 2011-12-11 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 6.49% | 30 M€ | +2.22% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi. ($) | ||
|---|---|---|---|---|---|---|
| +1.67% | +2.66% | +21.51% | +215.40% | 679B | ||
| -0.10% | -3.97% | -20.04% | +84.06% | 360B | ||
| +0.94% | +1.15% | -9.74% | -11.06% | 350B | ||
| +0.87% | -0.40% | +3.19% | +29.32% | 299B | ||
| +0.22% | +3.20% | +10.73% | -23.92% | 242B | ||
| +0.99% | -3.46% | -19.09% | +20.82% | 242B | ||
| +0.05% | +3.74% | +4.31% | +26.21% | 211B | ||
| +0.59% | -0.35% | -4.39% | +13.01% | 198B | ||
| +1.65% | +0.84% | -6.61% | -49.91% | 147B | ||
| +1.62% | +3.32% | -10.41% | +22.03% | 147B | ||
| Average | +0.66% | +0.16% | -3.05% | +32.60% | 287.55B | |
| Weighted average by Cap. | +0.45% | +0.09% | +0.16% | +64.22% |
| 2024 * | 2025 * | |
|---|---|---|
| Net sales | 45.27B 43.46B 41.07B 36.65B 65.08B 3,911B 72.02B 498B 183B 1,615B 170B 166B 7,062B | 58.33B 56B 52.92B 47.22B 83.85B 5,039B 92.8B 642B 236B 2,081B 219B 214B 9,099B |
| Net income | 11.12B 10.68B 10.09B 9.01B 15.99B 961B 17.7B 122B 44.96B 397B 41.72B 40.85B 1,735B | 19.41B 18.64B 17.61B 15.72B 27.91B 1,677B 30.89B 214B 78.46B 693B 72.8B 71.3B 3,028B |
| Net Debt | 22.05B 21.17B 20B 17.85B 31.7B 1,905B 35.08B 243B 89.11B 787B 82.69B 80.98B 3,440B | 16.55B 15.9B 15.02B 13.4B 23.8B 1,430B 26.34B 182B 66.91B 591B 62.09B 60.8B 2,583B |
More financial data
* Estimated data
Employees
43,000
Sector
Pharmaceuticals
Calendar
2025-02-06
- Q4 2024 Earnings Release
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-01-23 | 766.60 $ | +1.67% | 3,127,173 |
| 25-01-22 | 753.98 $ | +1.57% | 3,737,751 |
| 25-01-21 | 742.35 $ | +2.29% | 5,122,833 |
| 25-01-17 | 725.72 $ | -4.21% | 5,560,101 |
| 25-01-16 | 757.60 $ | +1.45% | 3,070,254 |
Delayed Quote Nyse, January 23, 2025 at 04:00 pm EST
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
753.98USD
Average target price
978.39USD
Spread / Average Target
+29.76%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- LLY Stock